- Home
- CIGL vs BRNS Comparison
CIGL vs BRNS Comparison
Compare CIGL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CIGL | BRNS |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Singapore | United Kingdom |
| Employees | 134 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.8M | 55.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CIGL | BRNS |
|---|---|---|
| Price | $1.65 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 45.8K | ★ 54.7K |
| Earning Date | 01-01-0001 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $0.56 |
| 52 Week High | $25.00 | $2.91 |
Technical Indicators
Market Signals| Indicator | CIGL | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 49.12 |
| Support Level | $1.52 | $0.56 |
| Resistance Level | $2.20 | $0.76 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.67 | 68.74 |
Price Performance
Historical ComparisonAbout CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.